tgAAVCF: Phase I/II

TGEN presented data from 23 patients in which administration of tgAAVCF to one sinus resulted in decreased IL-8 levels, which the company said could reduce inflammation associated with CF once the product is administered to the lung. Circulating vector or neutralizing antibodies to the vector were not detected, and the gene therapy was safe and well-tolerated. ...